Published in Kidney Int on September 01, 2003
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis (SLAM-2) | NCT02737202
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med (2008) 9.64
Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis (2010) 3.87
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int (2010) 2.12
Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol (2009) 2.02
Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int (2010) 1.81
Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol (2010) 1.65
Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2010) 1.63
Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2011) 1.62
Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant (2014) 1.55
Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol (2013) 1.50
Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant (2009) 1.46
Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int (2007) 1.44
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis (2011) 1.39
Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.32
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol (2009) 1.24
Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol (2014) 1.24
Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol (2009) 1.24
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol (2014) 1.23
Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int (2008) 1.21
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.21
Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol (2010) 1.20
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int (2015) 1.17
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.16
Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin J Am Soc Nephrol (2010) 1.16
Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int (2011) 1.13
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2011) 1.12
Imaging approaches to patients with polycystic kidney disease. Semin Nephrol (2011) 1.07
Developments in the management of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag (2008) 1.06
Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol (2010) 1.06
Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 1.05
Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 1.04
Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am J Transplant (2010) 1.03
Polycystic kidney disease: pathogenesis and potential therapies. Biochim Biophys Acta (2010) 1.02
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol (2016) 1.02
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis (2012) 1.01
Diagnosis and management of childhood polycystic kidney disease. Pediatr Nephrol (2010) 0.99
Detected renal cysts are tips of the iceberg in adults with ADPKD. Clin J Am Soc Nephrol (2012) 0.97
Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease. Pediatr Nephrol (2010) 0.95
Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs (2010) 0.94
CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiol Cell Physiol (2008) 0.94
Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2013) 0.94
Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2013) 0.91
Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. Am J Nephrol (2009) 0.90
Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2012) 0.88
Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2013) 0.87
Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol (2012) 0.86
Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients. Am J Pathol (2011) 0.85
Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renovasc Dis (2010) 0.85
Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice. Nephrol Dial Transplant (2010) 0.84
Urinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study. BMC Nephrol (2012) 0.84
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2015) 0.84
Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials (2011) 0.83
Supervised segmentation of polycystic kidneys: a new application for stereology data. J Digit Imaging (2014) 0.83
Novel treatments of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 0.83
Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective. Int J Nephrol Urol (2010) 0.82
Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol (2016) 0.81
Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic. BMC Nephrol (2012) 0.81
Novel mutations of PKD genes in the Czech population with autosomal dominant polycystic kidney disease. BMC Med Genet (2014) 0.81
ADPKD: Prototype of Cardiorenal Syndrome Type 4. Int J Nephrol (2010) 0.81
Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images. AJR Am J Roentgenol (2016) 0.81
Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. PLoS One (2014) 0.80
Kidney Disease Progression in Autosomal Recessive Polycystic Kidney Disease. J Pediatr (2016) 0.79
Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int (2017) 0.78
Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. BMC Med Genet (2015) 0.77
Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol (2015) 0.77
Novel methodology to evaluate renal cysts in polycystic kidney disease. Am J Nephrol (2014) 0.77
The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol (2016) 0.76
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring. J Vis Exp (2015) 0.76
Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol (2016) 0.76
Caffeine intake by patients with autosomal dominant polycystic kidney disease. Braz J Med Biol Res (2012) 0.76
Autosomal dominant polycystic kidney disease in children. Curr Opin Pediatr (2015) 0.76
Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease. Phys Med Biol (2016) 0.75
Association between Nephrolithiasis, Hypertension and Obesity in Polycystic Kidney Disease. Open Access Maced J Med Sci (2015) 0.75
Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Can J Kidney Health Dis (2017) 0.75
Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis. BMC Nephrol (2016) 0.75
Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol (2015) 0.75
Suitability of Patients with Autosomal Dominant Polycystic Kidney Disease for Renal Transcatheter Arterial Embolization. J Am Soc Nephrol (2015) 0.75
Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus. Can J Kidney Health Dis (2017) 0.75
Radiologic imaging of the renal parenchyma structure and function. Nat Rev Nephrol (2016) 0.75
Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Arch (2013) 0.75
Diagnostic Imaging of Autosomal Dominant Polycystic Kidney Disease. Pol J Radiol (2016) 0.75
Magnetic resonance microscopy of renal and biliary abnormalities in excised tissues from a mouse model of autosomal recessive polycystic kidney disease. Physiol Rep (2015) 0.75
Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report. Exp Ther Med (2017) 0.75
Intra- and inter-observer variability of functional MR urography (fMRU) assessment in children. Pediatr Radiol (2016) 0.75
Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS One (2017) 0.75
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA (2006) 9.55
MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol (2008) 6.91
Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol (2006) 6.86
Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene. Cell (2004) 6.10
The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol (2002) 5.58
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
Polycystic kidney disease. Annu Rev Med (2009) 4.78
The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet (2002) 4.54
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med (2003) 3.78
Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int (2002) 3.70
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Efficacy of maintenance treatment approaches for childhood overweight: a randomized controlled trial. JAMA (2007) 3.50
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Incidental findings in imaging research: evaluating incidence, benefit, and burden. Arch Intern Med (2010) 3.40
Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int (2008) 3.34
The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int (2011) 3.32
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med (2014) 3.25
PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet (2002) 3.21
The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat Genet (2006) 3.19
Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med (2014) 3.08
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging (2010) 3.03
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int (2009) 2.99
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol (2005) 2.92
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol (2007) 2.71
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int (2009) 2.60
Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int (2004) 2.55
Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet (2003) 2.55
Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int (2009) 2.52
Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int (2004) 2.47
Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int (2012) 2.46
High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis (2003) 2.41
Influence of nitrous oxide anesthesia, B-vitamins, and MTHFR gene polymorphisms on perioperative cardiac events: the vitamins in nitrous oxide (VINO) randomized trial. Anesthesiology (2013) 2.39
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology (2002) 2.34
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int (2003) 2.32
Missed dialysis sessions and hospitalization in hemodialysis patients after Hurricane Katrina. Kidney Int (2009) 2.31
Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int (2009) 2.30
High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. Am Heart J (2013) 2.30
Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology (2006) 2.28
Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 2.28
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
Methods for a multisite randomized trial to investigate the effect of constraint-induced movement therapy in improving upper extremity function among adults recovering from a cerebrovascular stroke. Neurorehabil Neural Repair (2003) 2.22
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21